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Summary A new strain of actinomycete designated PAL114, producing antimicrobial com-
pounds, was isolated from a Saharan soil in Ghardaïa, Algeria. Morphological and chemical studies 
showed that this strain belonged to the genus Streptomyces. Two bioactive compounds, named 
P41A and P41B, were extracted by dichloromethane from the cell-free supernatant broth of strain 
PAL114 and were purified by HPLC. Minimum inhibitory concentrations of the pure antibiotics were 
determined against yeasts, filamentous fungi and bacteria, most of which are pathogenic or 
toxigenic for human and multiresistant to antibiotics. The strongest activities were observed 
against Candida albicans M3 and Bacillus subtilis ATCC 6633. The chemical structures of the 
compounds were determined by spectroscopic analysis of UV—visible and 1H and 13C NMR spectra 
and spectrometric analysis of mass spectrum. The compounds P41A and P41B were identified as 
saquayamycins A and C, respectively. These compounds belong to the aquayamycin-group anti-
biotics, which are known in the literature for their anticancer and antibacterial activities.
Résumé Une nouvelle souche d’actinomycète désignée PAL114, produisant des composés 
antimicrobiens, a été isolée à partir du sol saharien de Ghardaïa, Algérie. Des études morpho-
logiques et chimiques ont permis de rattacher cette souche au genre Streptomyces. Deux 
composés actifs, nommés P41A et P41B, ont été extraits par le dichlorométhane à partir du filtrat 
de culture de la souche PAL114 et purifiés par HPLC. Les concentrations minimales inhibitrices
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des fractions actives pures ont été déterminées contre des levures, des champignons filamen-
teux et des bactéries, dont la plupart sont pathogènes ou toxinogènes pour l’homme et
multirésistants aux antibiotiques. L’activité la plus importante a été observée contre Candida
albicans M3 et Bacillus subtilis ATCC 6633. Les structures chimiques des molécules ont été
déterminées par analyses spectroscopiques (UV—visible et spectres RMN du 1H et du 13C) et
analyse spectrométrique (spectre de masse). Les composés P41A et P41B ont été identifiés
comme étant les saquayamycines A et C, respectivement. Ces composés appartiennent aux
antibiotiques du groupe des aquayamycines, connus dans la littérature pour leur activité
anticancéreuse et antibactérienne.
# 2013 Elsevier Masson SAS. Tous droits réservés.
Introduction
Considering the increasing resistance of pathogens to anti-
biotics, research has intensified in order to discover new
bioactive molecules. Among these pathogenic microorga-
nisms, fungi and yeasts cause serious diseases that affect
humans. Mycoses have increased dramatically during the last
decade. They rank fourth among nosocomial infections [23].
Bacterial infections pose also clinical problems, since many
works in the world and in Algeria have reported the emer-
gence of new bacterial strains resistant to multiple anti-
biotics, including some cephalosporins of third and fourth
generation [12,16,19].
Because of still perceptible deficiencies, which are obser-
ved during the treatment of fungal and bacterial diseases,
and considering the resistance of microorganisms to anti-
biotics, the current works are oriented toward the search for
new bioactive molecules. Among the molecules with anti-
microbial activity, the range of the antifungal compounds is
much more limited than those of the antibacterial
compounds [6]. This is why new non-toxic antifungal mole-
cules should be sought.
Actinomycetes are Gram-positive bacteria with a percen-
tage of guanine—cytosine higher than 55%, and most of them
produce mycelia. They are particularly interesting due to
their capacity to produce secondary metabolites with
diverse chemical structures [25]. They are especially known
for the production of antibacterial and antifungal antibio-
tics. It has been estimated that about two-third of the
natural antibiotics have been isolated from actinomycetes
[22]. The genus Streptomyces is known as the producer of the
largest number of antibiotics. It produces about 80% of the
antibiotics secreted by actinomycetes [7].
Our previous work showed the richness of antibiotic-pro-
ducing actinomycetes in the Algerian Saharan soil [18]. The
present work aims to study the antifungal and antibacterial
activities of a new strain of actinomycete against several
pathogenic and toxigenic microorganisms to human, and to
determine the chemical structure of the bioactive molecules
produced by this strain.
Materials and methods
Isolation and features of the actinomycete strain
A new strain of actinomycete, designated PAL114, was iso-
lated from a Saharan soil collected from Béni-isguen (lati-
tude, 328270N; longitude, 038400E; altitude, 468 m), Ghardaïa
province (South of Algeria). The dry soil sample was sus-
pended in sterile deionized water and diluted. Aliquots
(0.2 mL) of each dilution were spread onto chitin—vitamin
agar [8]. The medium was supplemented with cycloheximide
(80 mg/L) to inhibit the growth of any fungi. The plates were
incubated at 30 8C for two weeks.
The strain PAL114 was identified at the genus level on the
basis of morphological and chemical features. Both of these
criteria are widely used to identify the genera of actinomy-
cetes [11].
The morphological and cultural characteristics were
observed by naked-eye examination of 14 day-old cultures
grown on various International Streptomyces Project (ISP)
media: yeast extract—malt extract agar (ISP-2), oatmeal
agar (ISP-3), inorganic salts—starch agar (ISP-4) and glyce-
rol—asparagine agar (ISP-5) [21], and also on Bennett
medium [26]. The micromorphology was observed by light
microscopy.
For chemotaxonomic analyses, biomass was obtained by
growing strain PAL114 in ISP-2 broth in shake flasks [21] and
incubated at 30 8C for 4 days. Diaminopimelic acid isomers
and whole-cell sugar pattern were analyzed according to the
methods of Becker et al. [3] and Lechevalier and Lechevalier
[13], respectively.
Target microorganisms
Except strains with ATCC numbers, all other target micro-
organisms were isolated from diseased patients undergoing
antibiotic therapy, from medical equipment and from the
hospital environment sampled in five Algerian hospitals loca-
ted in Algiers and Béjaïa. The used target microorganisms
were yeasts (Candida albicans M1, M2, M3, IPA200 and Sac-
charomyces cerevisiae ATCC 4226), filamentous fungi
(Aspergillus carbonarius M333, Aspergillus flavus AF3, Fusa-
rium culmorum FC200 and Penicillium glabrum PG1) and
bacteria (Bacillus subtilis ATCC 6633, Staphylococcus aureus
S1 and Klebsiella pneumoniae E40). These microorganisms
were mostly pathogenic or toxigenic for humans and
multiresistant to antibiotics. All strains of C. albicans are
resistant to cycloheximide, itraconazole, nystatin, terbi-
nafine and thioconazole, and sensitive to amphotericin
B. Saccharomyces cerevisiae ATCC 4226 resists to the same
antifungal compounds, except cycloheximide and amphote-
ricin B. Aspergillus carbonarius M333, A. flavus AF3 and
Penicillium glabrum PG1 resist to cycloheximide but Fusa-
rium culmorum FC200 resists to cycloheximide, itracona-
zole, nystatin, terbinafine and amphotericin B. Bacillus
subtilis ATCC 6633 is a sensitive bacterium and resists only to
neomycin. Staphylococcus aureus S1 resists to gentamicin,
kanamycin, neomycin, spiramycin and vancomycin. Kleb-
siella pneumoniae E40 resists to cefotaxime and ceftazi-
dime.
Production and purification of bioactive
compounds
The production of bioactive compounds was conducted in
ISP-2 broth. This medium was chosen among several others
because of its very good results in our preliminary work. A
seed culture was prepared with the same medium and used
to inoculate 20 Erlenmeyer flasks of 500 mL, each containing
100 mL of medium. The cultures were incubated on a rotary
shaker (250 rpm) at 30 8C. The extraction of the active
compounds was carried out on the fifth day (previously
determined as being the day of the optimal production)
by centrifugation (5000 g, 20 min) of the culture broth to
eliminate cells. The cell-free supernatant was extracted
with an equal volume of dichloromethane. The organic
extract was concentrated to dryness by a rotary evaporator
under a vacuum at a temperature lower than 40 8C. The
resulting dry extract was recuperated in 0.5 mL of methanol
and bioassayed against Candida albicans M3, Aspergillus
carbonarius M333 and Bacillus subtilis ATCC 6633 by paper
disk diffusion method (disk diameter, 6 mm) at the rate of
30 mL per disk. These three target microorganisms were
selected from the twelve previously cited because they
represent the three groups of microorganisms studied (bac-
teria, yeast and filamentous fungi), and also because of their
higher sensitivity to the antibiotic activity (noticed in pre-
liminary work), thus, facilitating the detection of bioactive
compounds.
Preparative chromatography with silica gel plates (Merck
Art. 5735, Kiesselgel 60HF 254—366; 20  20 cm) was
employed for the partial purification of antimicrobial pro-
ducts. TLC plates were developed in the solvent system ethyl
acetate—methanol (100:15 v/v). The developed TLC plates
were air dried overnight to remove all traces of the solvents.
The separated compounds were visualized under UV at
254 nm (absorbance) and at 365 nm (fluorescence), and
the bioactive spot was detected by bioautography [5]. The
retention factor (Rf) of the bioactive spot was measured.
The final purification of bioactive compounds was carried
out by Waters reverse phase HPLC using an XBridge C18
(5 mm) column (200  10 mm, WATERS) with a continuous
linear gradient solvent system from 20 to 100% methanol in
water, a flow rate of 2 mL/min and UV detection at 220 nm
and 254 nm. All the peaks fraction were collected and tested
against Candida albicans M3, Aspergillus carbonarius M333
and Bacillus subtilis ATCC 6633, in order to detect the active
fractions and distinguish them from the non-active fractions.
The choice of these three target microorganisms was already
justified (as described above).
Structure determination of the active
compounds
These analyses were carried out with the antimicrobial
compounds purified by HPLC. The UV spectrum was given
with a SHIMADZU UV1605 spectrophotometer. The mass
spectrum was recorded on an LCQ ion-trap mass spectro-
meter (Finnigan MAT, San Jose, CA) with nanospray ion
electro-spray ionization (ESI) source (positive and negative
ion mode). 1H and 13C NMR spectroscopy were used for the
characterization of the active molecules. NMR sample was
prepared by dissolving 3 mg of each purified compound in
600 mL of CD3OD. All spectra were recorded on a Bruker
Avance 500 spectrometer equipped with a 5 mm triple
resonance inverse Z-gradient probe (TBI 1H, 31P, BB). All
the chemical shifts for 1H and 13C are relative to TMS using
1H (residual) or 13C chemical shifts of the solvent as a
secondary standard. The temperature was set at 298 K. All
the 1H and 13C signals were assigned on the basis of
chemical shifts, spin-spin coupling constants, splitting
patterns and signal intensities, and by using 1H—1H
COSY45, 1H—13C HSQC and 1H—13C HMBC experiments.
Gradient-enhanced 1H COSY45 was realized included 36
scans per increment. 1H—13C correlation spectra using a
gradient-enhanced HSQC sequence (delay was optimised
for 1JCH of 145 Hz) was obtained with 200 scans per
increment. Gradient-enhanced HMBC experiment was per-
formed allowing 62.5 ms for long-range coupling evolution
(340 scans were accumulated). Typically, 2048 t2 data
points were collected for 256 t1 increments.
Determination of minimum inhibitory
concentrations
Minimum inhibitory concentrations (MICs) of pure bioactive
compounds were performed using conventional agar dilution
method [17] on the twelve target microorganisms cited
above (see paragraph about target microorganisms). These
latter were inoculated onto Mueller Hinton medium for
bacteria and Sabouraud medium for yeasts and filamentous
fungi, containing different concentrations of active
compounds (1, 2, 5, 10, 20, 30, 50, 75 and 100 mg/mL). After
a growth period of 24—48 h at 37 8C for bacteria and 48—72 h
at 28 8C for fungi, the plates were examined for growth and
the lowest antibiotic concentration that inhibited the growth
of each organism was determined. Mueller Hinton and Sabou-
raud media without active compounds and inoculated with
target microorganisms was used as a control treatment.
Results
Identification of actinomycete to the genus level
The actinomycete strain PAL114 formed a well-developed
and ramified aerial mycelium with long spiraled chains of
spores carried by sporophores. The spores were oval and 1—
1.5  0.6—1 mm in size. The sporulation was good on all the
media used. The substrate mycelium was non-fragmented.
The strain showed good growth on ISP-2, ISP-3, ISP-4, ISP-5
and Bennett media. The aerial and substrate mycelia were
light to medium gray and light brown, respectively. Diffu-
sible pigment with light brown color was produced on ISP-2,
ISP-3 and Bennett media. The chemotaxonomic study sho-
wed the presence of LL-diaminopimelic acid isomer and
glycin in the cell wall and the presence of galactose, glucose
and ribose in the whole-cell hydrolysates.
Detection and purification of bioactive
compounds
The dichloromethane extract of the culture filtrate, pre-
viously dried and then redissolved in 0.5 mL of methanol, was
inoculated on paper disks (6 mm diameter) at a rate of 30 mL
per disk. The diameters of inhibition obtained were 20 mm
for Bacillus subtilis ATCC 6633, 20 mm for Candida albicans
M3 and 12 mm for Aspergillus carbonarius M333 (disk dia-
meter included).
On silica gel thin-layer chromatogram, the dichlorome-
thane extract migrated and gave one bioautographic frac-
tion, which was active against Candida albicans M3,
Aspergillus carbonarius M333 and Bacillus subtilis ATCC
6633. This fraction (Rf = 0.9 in ethyl acetate—methanol,
100:15 v/v) was injected in HPLC apparatus. Two active
compounds against these three microorganisms, named
P41A and P41B, were detected and eluted with 80% of
methanol in water at a retention times of 41.05 min and
41.56 min, respectively. A quantity of 3 mg of each
compound was obtained from 2 L of the culture filtrate.
Structure determination of bioactive compounds
The UV—visible spectra in methanol (data not shown) exhi-
bited a maximal absorption at 218, 317 and 425 nm for P41A
and at 218, 316 and 425 nm for P41B. The ESI—MS spectra
contained an ion peak at m/z 819.1 [MÿH]ÿ for P41A and at
m/z 823.2 [MÿH]ÿ for P41B (Fig. 1). Thus, the molecular
weights of these two compounds were M = 820 for P41A and
M = 824 for P41B.
The 1H and 13C chemical shifts of P41A and P41B
compounds are given in Table 1 and their structures can
be seen in Figs. 2 and 3.
The HSQC and HMBC spectra show 36 carbon signals for
P41A and P41B molecules. It was possible to discern 4 ketone
groups (dc 182.4 to 205.2), 3 hydroxyl groups (dc 70.9 to
157.8), 7 ether functions (dc 66.7 to 98.9) 4 sp
2—hybridized
carbons (dc from 116.4 to 145.2) and 11 sp
3—hybridized
carbons (dc 13s˙9 to 42.6) for P41a molecule, 5 ketone groups
(dc 182.4 to 205.2), 7 ether functions (dc 66.7 to 95.0) and 2
hydroxyl groups (dc 70.9 to 157.8) 6 sp
2—hybridized carbons
(dc from 116.4 to 145.2) and 9 sp
3—hybridized carbons (dc
13s˙9 to 42.6) for P41b compound. The hydrogens of the
hydroxyl group are not observed due to the rapid exchange
with MeOD. The 2D 1H—1H and 1H—13C (see Figs. 2 and 3)
permitted to establish the connectivity between all the
groups of the P41A and P41B molecules.
Minimum inhibitory concentrations
Minimum inhibitory concentrations of antimicrobial
compounds purified by HPLC are summarized in Table 2.
The MIC values obtained against the target microorganisms
the same for both active compounds. They were comprised
between 30—50 mg/mL for yeasts, 75—100 mg/mL for
filamentous fungi and 30—50 mg/mL for Gram-positive bac-
teria. Gram-negative bacterium tested was resistant. The
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Figure 1 Mass spectrometry profile of P41A (a) and P41B (b)
compounds produced by the actinomycete strain PAL114.
Spectre de masse des compose´s P41A et P41B produits par la
souche d’actinomyce`te PAL114.
[(Figure_2)TD$FIG]
Figure 2 Structure of antibiotic P41A (A) and COSY correla-
tions (B).
Structure de l’antibiotique P41A (A) et corre´lations COSY (B).
most sensitive microorganisms were Bacillus subtilis ATCC
6633 (30 mg/mL) and Candida albicans M3 (30 mg/mL).
Discussion
The strain PAL114 has an aerial mycelium producing chains of
spores, each carried by sporophores, and non-fragmented
substrate mycelium. This strain possesses in its wall, the LL-
diaminopimelic acid isomer and glycin, but does not have in
its cells diagnostic sugars, such as arabinose—galactose,
xylose—arabinose and rhamnose—galactose couples, or
madurose. These results indicate that strain PAL114 has a
chemotype IC as defined by Lechevalier and Lechevalier [13].
Based on the morphological and chemical characteristics,
strain PAL114 belonged to the genus Streptomyces [9].
Species of the genus Streptomyces are mainly known for
the production of bioactive molecules [22]. The antibiotics
Table 1 1H and 13C NMR data assignments of P41A and P41B compounds in CD3OD at 298 K. See Figs. 2 and 3 for numbering of
hydrogen and carbon atoms.
Donne´es RMN 1H and 13C des compose´s P41A et P41B dissous dans du CD3OD a` 298 K.
1H and 13C number 1H chemical shift (ppm) 13C chemical shift (ppm)
P41A P41B P41A P41B
1 1.33 1.33 13.91 13.91
2 4.61 4.61 70.10 70.10
3 — — 197.27 197.27
4 7.03 7.03 141.1 141.1
5 6.08 6.08 126.1 126.1
6 5.35 5.35 95.0 95.0
7 1.25 1.25 15.9 15.9
8 4.24 4.24 66.7 66.7
9 3.71 3.71 76.4 76.4
10 1.50 1.50 24.0 24.0
11 1.98 1.98 24.0 24.0
12 5.25 5.25 91.8 91.8
13 2.39 2.39 24.8 24.8
14 — — 81.9 81.9
15 2.00—2.32 2.00—2.32 42.61 42.61
16 — — 79.8 79.8
17 — — 79.5 79.5
18 — — 205.2 205.2
19 2.73—2.93 2.73—2.93 50.1 50.1
20 6.91 6.91 116.4 116.4
21 6.41 6.41 145.2 145.2
22 — — 139.3 139.3
23 — — 138.5 138.5
24 — — 182.4 182.4
25 — — 137.7 137.7
26 — — 131.0 131.0
27 — — 182.4 182.4
28 — — 157.8 157.8
29 — — 114.0 114.0
30 7.89 7.89 132.8 132.8
31 7.62 7.62 118.6 118.6
32 1.38 1.38 17.4 17.4
33 3.57 3.57 74.9 74.9
34 3.14 3.14 86.8 86.8
35 3.83 3.83 71.0 71.0
36 1.41—2.49 1.41—2.49 38.9 38.9
37 4.95 4.95 71.0 71.0
38 1.26 1.33 16.7 13.9
39 3.92 4.61 70.5 70.1
40 3.24 — 70.9 197.3
41 1.84 7.03 26.7 144.1
42 1.31—1.94 6.08 29.4 126.1
43 5.02 5.35 98.9 95.0
secreted by the species of this genus may be antibacterial
and/or antifungal (aminoglycosides, aromatics, glycopepti-
des, macrolides, polyenes, etc.) or, have cytostatic and
antitumor properties (anthracyclines, such as adriamycin
and daunomycin for example), and many of them have found
a fairly significant therapeutic application [10]. The same
species of actinomycete can produce several antibiotics
(sometimes belonging to different classes); however, the
same antibiotic can be produced by very different species
and sometimes even different genera [11,22]. Therefore,
this shows that the correlation between the production of
bioactive molecules and taxonomy is weak.
The structure of natural antifungal compounds produced
by Streptomyces (and other microbial genera) can be poly-
enic or non-polyenic. However, the number of these mole-
cules used in therapy is quite limited because of their toxicity
and sometimes their instability and insolubility [4], hence,
there is a need to continue the search for interesting new
antifungal molecules.
The strain PAL114 produces two molecules with antifun-
gal and antibacterial activities. The structure of these two
molecules, named P41A and P41B, was determined by NMR
and mass spectrometry, and they appear to be saquayamycin
A and C, respectively. They are antibiotics belonging to the
family of anthracycline, class of angucycline and group of
aquayamycin [15]. Among aquayamycin-group antibiotics,
saquayamycins are the most closely related to vineomycin
A1 [24]. They are known to be produced by actinomycetes,
especially Streptomyces nodosus, which produces saquaya-
mycins A, B, C and D [24]. It has been reported that saquaya-
mycin Z was produced by some strains of the genus
Micromonospora [2].
Saquayamycins are known as inhibitors of farnesyl-protein
transferase, an enzyme involved in cell division [14].
Figure 3 Structure of antibiotic P41B (A) and COSY correlations (B).
Structure de l’antibiotique P41B (A) et corre´lations COSY (B).
Table 2 Minimum inhibitory concentrations (MICs) of the
antimicrobial compounds produced by the strain PAL114
against several target microorganisms.
CMI des compose´s antimicrobiens produits par la souche
PAL114 contre plusieurs microorganismes-cibles.
Target microorganisms MIC (mg/mL) a
P41A P41B
Saccharomyces cerevisiae ATCC 4226 30 30
Candida albicans M1 50 50
C. albicans M2 50 50
C. albicans M3 30 30
C. albicans IPA200 50 50
Aspergillus carbonarius M333 75 75
A. flavus AF3 100 100
Fusarium culmorum FC200 75 75
Penicillium glabrum PG1 75 75
Bacillus subtilis ATCC 6633 30 30
Staphylococcus aureus S1 50 50
Klebsiella pneumoniae E40 > 100 > 100
a MIC values represent the average of two repetitions.
Therefore, they are cytotoxic, and used as anticancer agents
in chemotherapy [1,14]. Squayamycins A, B, C and D are
active against adriamycin-sensitive and adriamycin-resistant
sublines of P388 leukemia cells, and it has been reported that
saquayamycin A is particularly very active against cancerous
prostate cells [20,24]. Adriamycin is an anticancer compound
developed in the 1960s, belonging to the anthracycline
family, produced by actinobacteria of the genus Streptomy-
ces [27]. All saquayamycins are also active against Gram-
positive bacteria [2,24], but no antifungal activity was repor-
ted in the literature. This is the first time that the antifungal
activity (especially against yeasts) of saquayamycins is high-
lighted.
The results obtained in this work are interesting because
of the resistance of strains of C. albicans (M1, M2, M3 and
IPA200) used in our experimentation to cycloheximide, itra-
conazole, nystatin, terbinafine and thioconazole.
However, it should be noted that although the antifungal
activity of compounds P41A and P41B is interesting in vitro, it
is necessary to continue in vivo studies to really evaluate
their effectiveness, and it is only from these results that the
prospects for clinical application could be considered.
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